Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib vs Temsirolimus in Poor-Risk Renal Cell Carcinoma
NCT01392183Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2012
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pazopanib in clear cell renal cell carcinoma (ccRCC) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Progression Free Survival at 3 years. Started Oct 2012; status: completed.
02
Drugs
pazopanib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT01392183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01392183.